Haisco Pharmaceutical Group Co Ltd
SZSE:002653

Watchlist Manager
Haisco Pharmaceutical Group Co Ltd Logo
Haisco Pharmaceutical Group Co Ltd
SZSE:002653
Watchlist
Price: 33.81 CNY 0.03% Market Closed
Market Cap: 37.9B CNY
Have any thoughts about
Haisco Pharmaceutical Group Co Ltd?
Write Note

Operating Margin
Haisco Pharmaceutical Group Co Ltd

13.6%
Current
8%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.6%
=
Operating Profit
506.5m
/
Revenue
3.7B

Operating Margin Across Competitors

Country CN
Market Cap 37.7B CNY
Operating Margin
14%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 749.1B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 348B USD
Operating Margin
28%
Country US
Market Cap 251.1B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 150.1B USD
Operating Margin
22%
No Stocks Found

Haisco Pharmaceutical Group Co Ltd
Glance View

Market Cap
37.7B CNY
Industry
Pharmaceuticals

Haisco Pharmaceutical Group Co., Ltd. is an embodiment of relentless ambition and strategic foresight in China's burgeoning pharmaceutical landscape. Founded in 2000, the company quickly carved a niche for itself by focusing on the research, development, production, and sale of a diverse array of pharmaceutical products. Haisco's journey is rooted in an ethos of innovation and quality, as it sought to establish itself as a leader in the creation of anesthetics and antipyretic analgesics, among other critical therapeutic products. The company's prowess in research and development is clearly evident in its extensive pipeline and its state-of-the-art manufacturing facilities, which meet international standards. These capabilities allow Haisco to capture significant market share domestically and extend its reach into international markets. Where Haisco truly shines is in its operational model and financial acumen, driving its revenue streams through both business-to-business (B2B) and business-to-consumer (B2C) channels. On the B2B side, Haisco partners with hospitals, clinics, and other healthcare institutions to supply essential medications, ensuring a steady stream of revenue from bulk orders. Meanwhile, its direct-to-consumer sales strategy leverages in-depth market research to target retail pharmacies and end customers with a razor-sharp focus on effectiveness and affordability. By maintaining a dual-channel approach that capitalizes on economies of scale and robust distribution networks, Haisco not only amplifies its market penetration but also fortifies its financial performance. The company's strategic investments in technology and its commitment to stringent quality controls underpin its success, fostering trust and loyalty among consumers and partners alike.

Intrinsic Value
22.05 CNY
Overvaluation 35%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
13.6%
=
Operating Profit
506.5m
/
Revenue
3.7B
What is the Operating Margin of Haisco Pharmaceutical Group Co Ltd?

Based on Haisco Pharmaceutical Group Co Ltd's most recent financial statements, the company has Operating Margin of 13.6%.